Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.

Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA.

Clin Cancer Res. 2001 Jun;7(6):1600-9.

3.

Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.

Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F.

Oncol Rep. 2000 Sep-Oct;7(5):1123-8.

PMID:
10948350
4.

Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.

Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E.

Anticancer Res. 2000 Mar-Apr;20(2A):645-52.

PMID:
10810335
5.

Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.

Yu JJ, Bicher A, Ma YK, Bostick-Bruton F, Reed E.

Cancer Lett. 2000 Apr 14;151(2):127-32.

PMID:
10738106
6.

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E.

Int J Oncol. 2000 Mar;16(3):555-60.

PMID:
10675489
7.

Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.

Li Q, Zhang L, Tsang B, Gardner K, Bostick-Bruton F, Reed E.

Cell Mol Life Sci. 1999 Mar;55(3):456-66.

PMID:
10228559
8.
9.

Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.

Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E.

Int J Mol Med. 1998 Mar;1(3):617-20.

PMID:
9852275
10.

Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.

Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick-Bruton F, Reed E.

Int J Oncol. 1998 Nov;13(5):987-92.

PMID:
9772291
11.

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E.

J Biol Chem. 1998 Sep 4;273(36):23419-25.

12.
13.

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E.

Mutat Res. 1997 Sep;382(1-2):13-20.

PMID:
9360634
14.

Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.

Dabholkar MD, Berger MS, Vionnet JA, Overton L, Thompson C, Bostick-Bruton F, Yu JJ, Silber JR, Reed E.

Mol Carcinog. 1996 Sep;17(1):1-7.

PMID:
8876669
15.

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E.

J Clin Invest. 1994 Aug;94(2):703-8.

16.

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM.

Cancer Res. 1993 Aug 15;53(16):3694-9.

17.

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.

Cancer Res. 1993 Jan 15;53(2):242-7.

18.

Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E.

J Natl Cancer Inst Monogr. 1993;(15):83-8.

PMID:
7912534
19.

Expression of excision repair genes in non-malignant bone marrow from cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E.

Mutat Res. 1993 Jan;293(2):151-60.

PMID:
7678143
20.

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.

Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM, Reed E.

Environ Health Perspect. 1992 Nov;98:53-9.

21.

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E.

J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7.

PMID:
1433335
22.

Suramin in advanced platinum-resistant ovarian cancer.

Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE.

Eur J Cancer. 1992;28A(4-5):864-6.

PMID:
1524910
24.

Peripheral blood leukocytes as a surrogate marker for cisplatin drug resistance: studies of adduct levels and the repair gene ERCC1.

Parker RJ, Poirier MC, Bostick-Bruton F, Vionnet J, Bohr VA, Reed E.

Basic Life Sci. 1990;53:251-61. No abstract available.

PMID:
1704215
25.
26.

Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses.

Fisher RI, Bates SE, Bostick-Bruton F, Tuteja N, Diehl V.

J Immunol. 1984 May;132(5):2672-7.

PMID:
6609204
27.

Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures.

Fisher RI, Bostick-Bruton F, Sauder DN, Scala G, Diehl V.

J Immunol. 1983 Jun;130(6):2666-70.

PMID:
6222113

Supplemental Content

Loading ...
Support Center